LAKE FOREST, Ill.
March 25, 2013
/PRNewswire/ -- RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that its portfolio company, Argon Medical Devices, Inc. ("Argon" or the "Company"), entered into a definitive agreement to acquire the Interventional Products Business of Angiotech Pharmaceuticals, Inc. ("Angiotech"). The Interventional Products Business manufactures and markets disposable and re-usable biopsy products for the diagnosis of cancer, drainage catheter products, and vascular interventional products. The transaction is expected to be completed prior to the end of
subject to customary closing conditions.
The acquisition of the Interventional Products Business bolsters Argon's existing portfolio of interventional vascular products, adds additional biopsy product lines, and further leverages the Company's sales force within core call points. As part of the transaction, Argon will also acquire three dedicated manufacturing facilities in
, NY. Argon currently manufactures its products in facilities in
"The Interventional product franchise is well recognized by hospitals and physicians worldwide," said
Michael J. Hudson
, CEO of Argon. "The acquisition of these products strengthens the Argon portfolio and cements our Company's position as a key player in the Interventional Radiology, Cardiac Catheterization and Vascular Surgery markets."
The Interventional Products Business was created by RoundTable in 2003 as part of its American Medical Instruments Holdings, Inc. ("AMIH") investment. The AMIH business was run by Argon's current management team including:
, Argon's CEO;
, Argon's CFO; and
, Argon's President. AMIH combined the formerly independent Manan Medical, MD Tech, PBN Medical, and American Medical Instruments into a consolidated operating unit. Angiotech acquired the Interventional Products Business from RoundTable in 2006 as a part of its purchase of AMIH.